Immunologic risk stratification of pediatric heart transplant patients by combining HLA-EMMA and PIRCHE-II.
HLA-EMMA
PIRCHE-II
antibody mediated rejection (ABMR)
donor specific antibody
pediatric heart transplantation
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
11
2022
accepted:
28
02
2023
medline:
3
4
2023
entrez:
31
3
2023
pubmed:
1
4
2023
Statut:
epublish
Résumé
Human leukocyte antigen (HLA) molecular mismatch is a powerful biomarker of rejection. Few studies have explored its use in assessing rejection risk in heart transplant recipients. We tested the hypothesis that a combination of HLA Epitope Mismatch Algorithm (HLA-EMMA) and Predicted Indirectly Recognizable HLA Epitopes (PIRCHE-II) algorithms can improve risk stratification of pediatric heart transplant recipients. Class I and II HLA genotyping were performed by next-generation sequencing on 274 recipient/donor pairs enrolled in the Clinical Trials in Organ Transplantation in Children (CTOTC). Using high-resolution genotypes, we performed HLA molecular mismatch analysis with HLA-EMMA and PIRCHE-II, and correlated these findings with clinical outcomes. Patients without pre-formed donor specific antibody (DSA) (n=100) were used for correlations with post-transplant DSA and antibody mediated rejection (ABMR). Risk cut-offs were determined for DSA and ABMR using both algorithms. HLA-EMMA cut-offs alone predict the risk of DSA and ABMR; however, if used in combination with PIRCHE-II, the population could be further stratified into low-, intermediate-, and high-risk groups. The combination of HLA-EMMA and PIRCHE-II enables more granular immunological risk stratification. Intermediate-risk cases, like low-risk cases, are at a lower risk of DSA and ABMR. This new way of risk evaluation may facilitate individualized immunosuppression and surveillance.
Identifiants
pubmed: 36999035
doi: 10.3389/fimmu.2023.1110292
pmc: PMC10043167
doi:
Substances chimiques
HLA Antigens
0
Antibodies
0
Epitopes
0
Histocompatibility Antigens Class II
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1110292Subventions
Organisme : NIAID NIH HHS
ID : U01 AI104336
Pays : United States
Informations de copyright
Copyright © 2023 Ellison, Mangiola, Marrari, Bentlejewski, Sadowski, Zern, Kramer, Heidt, Niemann, Xu, Dipchand, Mahle, Rossano, Canter, Singh, Zuckerman, Hsu, Feingold, Webber and Zeevi.
Déclaration de conflit d'intérêts
M. Niemann works for PIRCHE AG, which develops and operates the PIRCHE web service. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer MM declared a past co-authorship with the author MN to the handling editor.
Références
J Heart Lung Transplant. 2022 Jul;41(7):952-960
pubmed: 35437211
Immunogenetics. 2020 Feb;72(1-2):119-129
pubmed: 31741009
J Am Heart Assoc. 2019 Aug 6;8(15):e011124
pubmed: 31339067
Front Immunol. 2021 Jul 06;12:703457
pubmed: 34305943
Hum Immunol. 2013 Nov;74(11):1474-7
pubmed: 23831255
Transplantation. 2002 May 15;73(9):1373-81
pubmed: 12023610
Transpl Int. 2014 Aug;27(8):793-804
pubmed: 24725030
Kidney Int. 2021 Oct;100(4):787-798
pubmed: 34186057
Transpl Int. 2020 Sep;33(9):1078-1088
pubmed: 32441827
Am J Kidney Dis. 2020 Jan;75(1):138-143
pubmed: 31515140
Front Immunol. 2021 Feb 26;12:631246
pubmed: 33717167
Nature. 1985 Apr 11-17;314(6011):537-9
pubmed: 3157869
Am J Transplant. 2018 Sep;18(9):2135-2147
pubmed: 29446208
Clin J Am Soc Nephrol. 2022 Aug;17(8):1204-1215
pubmed: 35649719
HLA. 2020 Jul;96(1):43-51
pubmed: 32227681
Transplantation. 2009 Sep 27;88(6):791-8
pubmed: 19920778
Hum Immunol. 2020 Dec;81(12):671-674
pubmed: 33041085
Am J Transplant. 2018 Sep;18(9):2163-2174
pubmed: 29442424
Transplantation. 2011 May 27;91(10):1153-8
pubmed: 21544036
J Heart Lung Transplant. 2019 Sep;38(9):972-981
pubmed: 31324444
Int J Immunogenet. 2022 Feb;49(1):30-38
pubmed: 34904369
Front Immunol. 2016 Dec 14;7:582
pubmed: 28018349
Nat Rev Immunol. 2004 Apr;4(4):308-12
pubmed: 15057789
Hum Immunol. 2019 Aug;80(8):568-572
pubmed: 30926351
Tissue Antigens. 2011 Jun;77(6):525-34
pubmed: 21410655
J Heart Lung Transplant. 2015 Jul;34(7):950-7
pubmed: 25727771
Transplantation. 2005 Feb 15;79(3 Suppl):S8-S11
pubmed: 15699753
Front Immunol. 2012 Jul 13;3:184
pubmed: 22811678
Kidney Int. 2021 Nov;100(5):1012-1022
pubmed: 34246656
Am J Transplant. 2018 Sep;18(9):2148-2162
pubmed: 29673058
Transplantation. 2011 Jan 27;91(2):183-90
pubmed: 21079553
J Immunol. 2011 Jul 15;187(2):1023-30
pubmed: 21677143
Annu Rev Immunol. 1993;11:331-60
pubmed: 8476565
Hum Immunol. 2020 Jul;81(7):330-336
pubmed: 32307126
Am J Transplant. 2016 Feb;16(2):672-8
pubmed: 26552037
Curr Opin Nephrol Hypertens. 2020 Nov;29(6):630-635
pubmed: 32889983